Degron Therapeutics has secured $40 million in a Series A extension to advance its molecular glue degrader pipeline, strengthening its position in the emerging targeted protein degradation field. The financing brings the clinical-stage biotechnology company’s total capital raised to $95 million. Degron said the new funds will support clinical development, preclinical pipeline progress, and further expansion of its proprietary GlueXplorer platform.
Financing Details and Investor Support
The round was led by LAPAM CAPITAL and included participation from GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures, and GAGE Capital. The investor syndicate reflects continued interest in drug discovery platforms designed to address disease targets that have historically been difficult or impossible to reach with conventional small molecules. According to the company, the funding will help accelerate both its lead oncology program and additional immunology assets.
Lead Clinical Program
A major focus of the financing is DEG6498, Degron’s lead molecular glue degrader targeting Human antigen R, also known as HuR. The company describes DEG6498 as a first-in-class, orally bioavailable small molecule designed to degrade HuR by inducing an interaction between the E3 ubiquitin ligase component cereblon and the RNA-binding protein. The program entered clinical development in late 2025, with the first patient dosed in November, and is now being evaluated in a Phase 1 dose-escalation study in patients with advanced solid tumors.
Platform and Pipeline Expansion
HuR has been associated with cancer, inflammation, and metabolic disease, but it has generally been considered difficult to drug using traditional approaches. Degron’s strategy is to use molecular glue degraders to redirect the cell’s protein disposal machinery toward disease-driving proteins that lack conventional binding pockets. The company said proceeds will also support two immunology programs as they move toward development candidate selection in 2026.
GlueXplorer and R&D Strategy
Founded in 2021 by ShanghaiTech University professor Yong Cang, Degron has built its discovery work around GlueXplorer, a de novo molecular glue degrader platform. The company says the platform includes more than 10,000 structurally differentiated compounds spanning over 150 novel non-IMiD cores, supported by complementary screening and validation systems. This infrastructure has enabled Degron to develop a pipeline across oncology, inflammation, metabolic disorders, and rare diseases.
The Series A extension gives Degron additional capital to push its first clinical program forward while broadening its preclinical pipeline. The company’s progress comes as targeted protein degradation continues to attract investor and industry attention for its potential to address previously inaccessible disease targets. With operations in Shanghai, Hangzhou, and San Diego, and partnerships including an ongoing collaboration with Takeda, Degron is positioning itself as a cross-border biotechnology company focused on next-generation small-molecule medicines.